Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) have received grant of US Patent for a method of treatment on its topical wound-healing composition.
October 31 2023 - 6:56AM
Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals
A/S) have received grant of US Patent for a method of treatment on
its topical wound-healing composition.
31 October 2023
Announcement no. 41
Pharma Equity Group’s subsidiary company
(Reponex Pharmaceuticals A/S) have received grant of US Patent for
a method of treatment on its topical wound-healing
composition.
Reponex Pharmaceuticals A/S (Reponex) today
announced that the United States Patent and Trademark Office
(USPTO) s approved the US patent application 16/366.898. This
application describes a method of treating a chronic wound by the
topical application of a hydrogel containing granulocyte-macrophage
colony-stimulating factor (GM-CSF), sucralfate and hyaluronan to
accelerate wound healing.
“Reponex’s treatment combines three active
substances that accelerates the healing of chronic wounds such as
venous and diabetic leg ulcers. We are pleased that the USPTO have
now approved our patent application for our treatment method, the
USA being such an important commercial area,” says Thomas Kaas
Selsø, CEO of Pharma Equity Group A/S.
According to Grand View Research, the global
wound care market size was valued at USD 21.4 billion in 2022 and
is expected to grow at a compound annual rate (CAGR) of 4.15% from
2023 to 2030. Of this, the market in the USA accounts for approx.
USD 8 billion in 2022. The chronic wounds segment held the largest
share of approx. 60% in 2022.
The patent is valid until 2039.
For further information, please
contact
Thomas Kaas Selsø, CEOTelephone: +45 4022
2114E-mail: tks@pharmaequitygroup.com
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the
Nasdaq Copenhagen stock exchange, is fully dedicated to advancing
the medical projects of its subsidiary, Reponex Pharmaceuticals
A/S. With an unwavering focus on healthcare, Pharma Equity Group's
primary objective is to bring significant value to Reponex
Pharmaceuticals' medical projects.
The company is committed to providing extensive
support, resources, and expertise to drive the development and
success of these projects. As a strategic partner, Pharma Equity
Group works closely with Reponex Pharmaceuticals, prioritizing the
advancement of innovative medical solutions and breakthrough
therapies. Every effort is currently directed towards ensuring the
utmost success and impact of Reponex Pharmaceuticals' medical
projects, with an unwavering dedication to improving global
healthcare outcomes. Only when the full potential of Reponex
Pharmaceuticals has been unfolded is the intention to explore
opportunities to invest in other companies. This approach ensures a
strong commitment to the current medical projects and their
development, while – on the longer term – remaining open to new
strategic investments for continuous growth.
- 2023-10-31 Announcement no 41 - UK
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jul 2023 to Jul 2024